Research - TNFa001: Tumor Necrosis Factor-alpha, TNF-alpha

Products:

AGE

BioPrime Antibodies

BioPrime Staining Reagents

Proteins and Peptides

VECTOR Reagents

Products> Research

TNFa001: Tumor Necrosis Factor-alpha, TNF-alpha

Print page

place in shopping cart

Price: 335 € / 0.5 mg

Monoclonal Antibodies

Origin:	Mouse

Isotype:	IgG1

Clone:	NYRhTNFa-E2

Format:	lyophilized

Quantity:	0.5 mg

Reconstitution:	0.5 ml sterile distilled water

Concentration:	1 mg/ml after reconstitution

Presentation:	Ionexchange purified mouse IgG

Immunogen:	recomb. human TNF-alpha

Specificity:	human TNF-alpha

Species Specificity:	Human, cross-reactivity with other species not determined

General Information:	Tumor Necrosis Factor alpha is a cytokine which is expressed by macrophages, monocytes, neutrophils, NK-cells and CD4+ T-cells. CD8-positive T-cells secrete little or no TNF-alpha. The synthesis of TNF-alpha may be induced by many different factors like Interferon, IL-2, GM-CSF etc..

Special properties:	The antibody against TNF-alpha is well suited for the detection of the cytokine in free and intracellular form.

Applications:	Direcr ELISA, Western Blot, Immunoprecipitation, intracellular staining

Secondary reagents:	Anti-mouse IgG conjugate, biotinylated (e.g. VECTOR Art. No. BA-2000 or BA-2001), HRPO (Art. No. PI-2000) FITC (Art. No. FI-2000 or FI-2001)

Storage:	2-8°C

References:
1. Nemoto Y, Kanai T, Makita S, Okamoto R, Totsuka T, Takeda K, Watanabe M. Bone marrow retaining colitogenic CD4+ T cells may be a pathogenic reservoir for chronic colitis. Gastroenterology. 2007 Jan;132(1):176-89.

2. Ewing P, Miklos S, Olkiewicz KM, Muller G, Andreesen R, Holler E, Cooke KR, Hildebrandt GC. Donor CD4+ T-cell production of tumor necrosis factor alpha significantly contributes to the early proinflammatory events of graft-versus-host disease. Exp Hematol. 2007 Jan;35(1):155-63.

3. Li JM, Waller EK. The yin and yang of adaptive immunity in allogeneic hematopoietic cell transplantation: donor antigen-presenting cells can either augment or inhibit donor T cell alloreactivity. Adv Exp Med Biol. 2007;590:69-87.

4. Fowler DH, Odom J, Steinberg SM, Chow CK, Foley J, Kogan Y, Hou J, Gea-Banacloche J, Sportes C, Pavletic S, Leitman S, Read EJ, Carter C, Kolstad A, Fox R, Beatty GL, Vonderheide RH, Levine BL, June CH, Gress RE, Bishop MR. Phase I clinical trial of costimulated, IL-4 polarized donor CD4+ T cells as augmentation of allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2006 Nov;12(11):1150-60.

Notes:
*BIOLOGO's antibodies are intended for in vitro research use only. They must not be used for clinical diagnostics and not for in vivo experiments in humans or animals.